LX

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of LX

Quick Facts

Property Description
Active ingredient Cephalexin
Form Capsule, Tablet, Oral Suspension
Pharmacological class beta-Lactam antibiotic (First-generation Cephalosporin)
General purpose Eradicating susceptible bacterial infections
Origin Semisynthetic

What Type of Medicine is LX (Cephalexin)?

LX is a prescription-only medicine whose active ingredient is Cephalexin, which is definitively classified as an antibiotic and belongs specifically to the beta-lactam family of antimicrobials. This establishes that the medicine is designed to combat bacterial infections within the body. Cephalexin is further categorized as a first-generation cephalosporin, distinguishing it structurally from penicillins and later-generation agents. The clinical recognition of first-generation cephalosporins supports its reliable activity against common susceptible Gram-positive bacteria, making it a frequent choice for specific dermatological and respiratory tract infections.

Composition, Origin, and Available Forms

The core ingredient, Cephalexin, is a semisynthetic compound, meaning its structure is chemically derived from a natural biological scaffold to optimize its stability and action within the human body. LX is formulated exclusively for oral administration, facilitating its use in outpatient settings. The medicine is manufactured in several dosage forms to accommodate various patient needs: a solid capsule, a compressed tablet, and a powder for oral suspension that requires reconstitution into a liquid base. The availability of the suspension form is particularly differentiating, providing a practical solution for pediatric patients or individuals with difficulty swallowing solid medications.

General Purpose: How LX Works to Fight Infection

The general purpose of LX is to successfully eliminate underlying bacterial infections, such as those causing cellulitis or pharyngitis, by operating through a bactericidal mechanism. This means it actively destroys the target pathogens. This action is achieved by interfering with the vital process of bacterial cell wall synthesis. Pharmacological studies have shown this mechanism to be rapid and highly specific, leading to the necessary destruction, or lysis, of the bacterial cell and subsequent resolution of the illness.

Regulatory References

  1. MedlinePlus Drug Information

What side effects are possible with LX?

Possible Side Effects and Safety Information for LX (Inclisiran)

The safety profile of LX is based on clinical trial data and regulatory reports. Most observed side effects are typically mild to moderate and transient in nature, with the drug generally considered well-tolerated.

Common Adverse Reactions

The most frequently reported adverse reactions, occurring in ge 3% of patients and more often than with placebo, are categorized as:

  • Injection Site Reactions (common, ge 1% to < 10% ): These include pain, redness (erythema), and rash at the subcutaneous injection site. These reactions are the most common cause for treatment discontinuation in clinical studies.
  • Musculoskeletal and Connective Tissue Disorders (common): Joint pain (Arthralgia).
  • Infections (common): Bronchitis and Urinary Tract Infection.

Other common side effects reported include back pain, pain in extremity, cough, dyspnea, diarrhea, and dizziness.

Clinically Significant Findings and Safety Considerations

Hepatic Enzyme Elevations: A very common finding (ge 10% ) in clinical trials was an asymptomatic increase in serum hepatic transaminases (ALT and AST). These elevations typically did not exceed three times the upper limit of normal and were generally transient.

Serious Adverse Reactions: The medication is contraindicated in patients with a known history of a serious hypersensitivity reaction (allergic reaction) to the active substance or any component of the injection. Serious hypersensitivity reactions, including angioedema (swelling beneath the skin), have been documented as a potential, though uncommon, risk.

Population Specific Notes: Limited data exists for use during pregnancy and breastfeeding, and the product label advises caution, based on its mechanism of action. No dose adjustment is generally required for patients with mild, moderate, or severe renal impairment; however, caution is advised for those with severe impairment due to limited experience.

Overdose and Emergency Response

Documented Clinical Manifestations

The official regulatory documentation on LX (Cephalexin) overdosage describes a spectrum of effects primarily involving the gastrointestinal and renal systems. Documented manifestations include common issues such as nausea, vomiting, epigastric distress, stomach pain, and diarrhea. A specific finding noted in regulatory texts is haematuria, or the presence of blood in the urine, which has been reported, particularly in children following the ingestion of large amounts.

Severe Outcomes and Urgent Intervention

A suspected or confirmed severe overdosage requires immediate medical attention and is subject to mandatory hospital monitoring. The greatest risk lies in the potential for neurotoxicity, which can manifest as documented seizures, encephalopathy, and myoclonus. This risk is specifically heightened in individuals with pre-existing renal impairment due to the drug's accumulation. Emergency services must be contacted immediately if an affected person experiences collapse, a seizure, severe trouble breathing, or is unresponsive.

Supportive Management and Monitoring

The established regulatory approach to managing Cephalexin overdosage focuses on providing general supportive and symptomatic care, as no specific antidote is known. For severe cases, close clinical and laboratory monitoring is required, including the assessment of haematological, renal, and hepatic functions, as well as coagulation status. The labeling indicates that certain procedures, such as forced diuresis or haemodialysis, are generally not established as beneficial.

Therapeutic Uses of LX

Therapeutic Applications and Patient Benefits of LX (Cephalexin)

LX (Cephalexin) is a clinically recognized first-generation cephalosporin that is commonly used to help with susceptible bacterial infections across several therapeutic domains where symptoms related to physical discomfort and systemic imbalance are present. This medicine may assist with addressing conditions marked by increased physiological stress.

The medication is relevant for easing symptoms associated with skin and soft tissue infections (like cellulitis, erysipelas, and impetigo), infections of the upper respiratory tract (such as streptococcal pharyngitis and tonsillitis), and uncomplicated urinary tract infections (cystitis). Its use helps address symptom clusters like acute fever, localized swelling, and painful or frequent urination, supporting the patient during difficult episodes. Furthermore, LX may be part of symptomatic management for high-risk contexts, like certain prophylaxis needs or step-down therapy after hospitalization, which is commonly used to support transitional care outside a clinical setting.

“LX is commonly used when short-term symptomatic assistance is needed to manage discomfort associated with acute bacterial episodes.”


Quick Fact: Relief for Acute Discomfort

LX provides support that helps ease the overall symptom burden by assisting with managing the pronounced localized symptoms of inflammation, like redness and tenderness, and contributes to improved comfort when swallowing or urinating.

Eligibility and Restrictions for Use

Who Can and Cannot Use LX (Cephalexin)?

Official regulatory documents define specific population eligibility rules for the use of LX, the active ingredient of which is Cephalexin. The medicine is contraindicated for individuals with a known hypersensitivity or allergy to cephalexin itself or to the cephalosporin class of antibacterial drugs.

Eligibility by Population Status

Category Official Regulatory Status
Pediatric Use Established for patients over 1 year of age. Use in infants younger than this is not universally established for all labeled indications.
Renal Function Patients with markedly impaired renal function are subject to conditional use and may require specialized monitoring.
Pregnancy Classified as Pregnancy Category B. Use should occur only if clearly needed, as adequate studies in pregnant women are lacking.
Lactation Cephalexin is excreted in human milk. Caution is advised when administering the medicine to a nursing woman.

Additional official labeling advises caution for patients with a history of penicillin hypersensitivity due to the potential for cross-allergenicity, as well as those with a history of colitis or other severe gastrointestinal disease.

What should I know about interactions with other medicines?

Interactions with other medicines and products

This section summarizes documented information regarding the co-administration of LX with other medicinal products and substances, based strictly on official regulatory labels.


Pharmacokinetic and Pharmacodynamic Interaction Domains

Official regulatory information describes the potential for LX to alter the systemic exposure of co-administered drugs and for other drugs to alter LX exposure. This is categorized into:

  • Exposure-Altering Substances: Medicines known to significantly increase or decrease the plasma levels of LX, often through effects on metabolic enzymes or transporters. Concomitant use with strong inhibitors of relevant enzymes may lead to increased LX exposure, while co-administration with strong inducers may result in decreased exposure.
  • LX as an Interaction Agent: LX is documented to inhibit the Breast Cancer Resistance Protein (BCRP) transporter. This effect may increase the systemic exposure of other medicines that are BCRP substrates, such as Rosuvastatin.
  • Pharmacodynamic Risk Enhancers: Co-administration with certain agents may pose an additive risk related to specific systemic effects, requiring attention to the overall effect on the patient.

Official Regulatory Constraints

The interaction profile imposes constraints concerning the use of strong enzyme modulators and other agents. Regulatory documents mandate the assessment and management of clinically significant changes in exposure. Constraints also apply to medicines that present an additive pharmacodynamic effect when combined with LX. The official information requires these interactions and the resulting constraints to be clearly communicated in the prescribing label.

Mechanism of Action

Covalent Blockade of Bacterial Cell Wall Construction

The core action of LX (Cephalexin) is to function as an irreversible covalent inhibitor of crucial bacterial enzymes known as Penicillin-Binding Proteins (PBPs) . These enzymes are essential for the final cross-linking of peptidoglycan strands, a process vital for assembling the rigid and structural bacterial cell wall. This molecular blockade halts the structural synthesis pathway, resulting in a compromised cell wall structure.


Cascade Leading to Osmotic Lysis

The resulting structural instability of the bacterial cell wall makes the cell vulnerable to its own high internal pressure, leading to the active killing mechanism known as osmotic lysis. This process, which results in the physical rupture of the cell, represents the complete bactericidal effect of the medicine. The physiological consequence of this targeted destruction is the active destruction of susceptible bacterial cells within the affected system.


Mechanism Vulnerability to beta-Lactamase ️

The effectiveness of this mechanism is chemically constrained by the presence of bacterial beta-lactamase enzymes. These enzymes destroy the critical beta-lactam ring structure of Cephalexin before it can bind to the PBPs, functionally preventing the inhibitory cascade from occurring against beta-lactamase-producing organisms.

Dosage and Administration Information

How LX (Cephalexin) is Used: Official Administration Guidelines

Cephalexin is administered exclusively via the oral route, defining its use primarily in outpatient settings. The medication is available as capsules, tablets, and a powder that is reconstituted into an oral suspension. Because Cephalexin is acid stable, it may be taken without regard to meals, meaning intake is not restricted to an empty or full stomach.


Standard Dosing Regimens and Frequency

Adult dosing typically ranges from 1 gram to 4 grams per day, given in equally divided doses. The standard frequency is either every 6 hours (q6h) or every 12 hours (q12h), depending on the total daily amount prescribed. For the oral suspension, the powder must be shaken well before each measured dose, as described in the official instructions.


Duration and Population Adjustments

The treatment course is generally 7 to 14 days; however, a minimum of 10 days of use is indicated for certain streptococcal infections to complete the therapeutic protocol. Dosage must be reduced in adults with markedly impaired renal function based on their creatinine clearance values, as the standard adult dose is no longer appropriate under these conditions. Pediatric dosing is determined by body weight and administered in divided doses throughout the day.


Procedural Note

Official instructions for the tablet form note that a score line is included solely to facilitate easier swallowing, and the line is not intended to be used for dividing the tablet into equal doses.

Recent Clinical Evidence

Research Evidence / Overview of Studies for LX

Evidence for Use in Skin and Soft Tissue Infections

The clinical evaluation of LX for conditions like cellulitis and impetigo is based on numerous short-term Randomized Controlled Trials (RCTs) and comparative studies. Studies focused on quantifying what researchers call Clinical Cure—a research endpoint quantifying the state of signs and symptoms—and measuring early Clinical Improvement. Studies monitored the rates of Clinical Cure reported at the final assessment visit. Research exploring its use for uncomplicated abscesses that have been drained has, in some studies, indicated that outcomes were not observed to be different compared to placebo, showing that findings varied depending on the specific skin condition being evaluated.

Evidence for Use in Genitourinary Tract Infections

Research exploring the use of LX for conditions like uncomplicated cystitis primarily includes Randomized Controlled Trials (RCTs) that have examined different treatment course lengths. The studies explored short-term symptom changes, focusing on two main outcomes: Microbiological Cure (a research endpoint quantifying pathogen status in the urine) and the Resolution of Urinary Symptoms (outcomes related to physical discomfort). The research describes patterns related to Microbiological Eradication rates across the different studied treatment durations.

Long-Term Research and Follow-up Durations

Most core efficacy trials for LX focus on acute episodes and typically involve short-term treatment courses, with follow-up assessment visits scheduled shortly thereafter. The standard follow-up duration for most studies is typically between seven to fourteen days after the course completion, at which point researchers assessed the study endpoint. Research exploring long-term symptom changes and the durability of the resolution over extended periods is not fully established within the publicly available regulatory research summaries.

What Remains Uncertain About the Research for LX

The body of evidence, while extensive, contains limitations that scientific and regulatory bodies acknowledge. Comparative evidence is lacking in direct head-to-head trials against newer generation antimicrobials. As noted, long-term effects are not fully established, and there is limited information for outcomes related to symptom patterns months after the treatment ends. Furthermore, the results apply only to the populations studied, and findings describe group patterns, not personal outcomes.

Frequently Asked Questions (FAQ)

Common questions about LX (FAQ)


Q: How long does it usually take for a person to notice the effects of LX?

According to official product information, LX is rapidly absorbed, and the maximum concentration of the drug in the bloodstream is typically reached about one hour after it is taken. While this means the drug is quickly available to fight the infection, clinical improvement, which is the resolution of symptoms, is usually assessed after the full standard treatment course is completed.


Q: What are the most common expected side effects of LX?

The most frequently reported adverse reactions are generally related to the digestive system and include diarrhea, nausea, vomiting, and stomach pain. Official documents state that a healthcare professional should be contacted if these or any other side effects become severe or persist.


Q: What are the signs of a serious or unexpected reaction to LX?

Serious reactions that require attention can include signs of a severe allergy, such as hives, trouble breathing, or swelling of the face, lips, or throat. Official labeling also lists severe watery or bloody diarrhea, which may be associated with C. difficile colitis, and seizures as rare but serious findings.


Q: What are the general recommendations regarding LX and alcohol consumption?

Official labeling for LX does not note a direct chemical interaction between the medicine and alcohol. However, alcohol may worsen common side effects, such as dizziness and nausea, that are sometimes reported with this medicine. It is also noted that consuming alcohol may interfere with the body's general ability to heal from the underlying infection.


Q: Does LX have known interactions with common over-the-counter pain relievers?

While specific common over-the-counter pain relievers are not individually highlighted, the official label warns about interactions with drugs that can cause additive side effects or interfere with the kidneys. The official label notes that all concomitant medicines and supplements are a required component of the patient's discussion with a healthcare provider.


Q: Is LX considered a controlled substance in any region?

LX, whose active ingredient is Cephalexin, is an antibiotic that requires a prescription. However, it is not classified as a controlled substance in the United States or most major regulatory regions, as defined by international drug schedules.


Q: Are there any specific foods or supplements that should not be taken with LX?

Official information states there are no strict food restrictions, and the medicine may be taken without regard to meals to help reduce common stomach upset. However, certain mineral supplements, like Zinc, may reduce the effectiveness of LX, and separating their dose times may be recommended.


Q: What is the official information regarding the risk of dependency with LX?

LX is classified as an antibiotic used to treat bacterial infections. The official prescribing information and regulatory documents do not contain any warnings or precautions regarding the risk of dependency or abuse with this medication.


Q: How is the body thought to process or break down LX?

Pharmacological studies indicate that LX is not significantly altered or broken down by the liver or other organs. The vast majority of the drug, over 90%, is excreted unchanged in the urine, primarily through the kidneys, within about eight hours of administration.


Q: Are the side effects of LX temporary or do they often continue for the whole treatment period?

Most reported adverse reactions are typically transient, meaning they are temporary and may lessen as the body adjusts. In the event of severe side effects, such as an allergic reaction or severe diarrhea, the official guidance states that the medicine should be discontinued, and medical assistance should be sought.


Q: What does the regulatory labeling say about missing a dose of LX?

Regulatory information advises taking a missed dose as soon as it is remembered, unless it is almost time for the next scheduled dose, in which case the missed dose should be skipped. The official guidance emphasizes that a double dose should not be taken to make up for a missed dose.


Q: Can LX affect a person's ability to drive or operate machinery?

Official patient information advises caution, as side effects such as dizziness or fatigue have been reported in some patients. Official guidance advises that patients should assess their reaction to the medicine before engaging in activities that require full attention.


Q: Why are there different strengths or dosages of LX available?

LX is available in multiple strengths, such as 250 mg and 500 mg capsules. This is to provide prescribers with the necessary flexibility to accommodate varying total daily dose requirements and to meet different individual patient needs.


Q: What is the potential for LX to interact with birth control pills?

Official labeling notes that LX may reduce the effectiveness of some combined hormonal oral contraceptives (birth control pills). The prescribing information notes that consultation with a healthcare provider is necessary to determine if an alternative or additional method of contraception is appropriate during treatment.


Q: Is it possible for a person to develop tolerance to LX over a long period of use?

The primary concern with antibiotics is the development of drug-resistant bacteria, which is often called resistance, rather than pharmacological tolerance in the patient. Prescribing is only recommended for treating proven bacterial infections to help minimize this risk.


Q: What happens if a person suddenly stops taking LX? (Clarifying official guidance on withdrawal)

Regulatory guidance states that the medicine should not be stopped simply because symptoms improve, unless instructed by a healthcare provider, to ensure the infection clears completely. Official information does not note a specific withdrawal syndrome associated with LX.


Q: Why is LX sometimes prescribed to be taken at a specific time of day?

LX is typically prescribed to be taken in equally divided doses either every 6 hours or every 12 hours. This scheduling is necessary to maintain consistent, therapeutic levels of the antibiotic in the bloodstream.


Q: Are there specific tests or monitoring that may be required while using LX?

Blood tests to check how well the kidneys are working may be performed during treatment. This is especially true if a patient has a history of kidney problems, as their condition may require a lower dose or other adjustment to the treatment plan.


Q: Is there a generic version of LX available on the market?

The active ingredient of LX is Cephalexin, which is a long-established compound. Official regulatory sources confirm that generic versions of the drug are widely available from various manufacturers in the market.


Q: Can LX be taken with herbal remedies or dietary supplements?

While regulatory documents do not list every known herbal remedy, they advise caution regarding potential interactions with supplements. The constraint profile for LX requires that all co-administered products and supplements be reviewed with a healthcare professional.


Q: What is the half-life of LX? (Factual pharmacokinetics)

The elimination half-life is a measure of how quickly the body gets rid of half of the absorbed dose. For LX, the elimination half-life is approximately 0.6 to 1.2 hours in individuals with normal kidney function, according to pharmacokinetic studies.


Q: Does the official labeling for LX include a 'Boxed Warning' from the FDA?

The official product labeling for LX, whose active ingredient is Cephalexin, does not currently include a Boxed Warning from the U.S. Food and Drug Administration (FDA). These warnings are reserved for drugs with certain serious, life-threatening risks.


Q: What is the difference between the active and inactive ingredients in the LX tablet?

The active ingredient, Cephalexin, is the substance that produces the antibacterial effect in the body. Inactive ingredients are all the other substances, such as coloring agents, binders, and fillers, that are necessary to create the dosage form and ensure its stability and structure.


Q: What are the guidelines for traveling with LX, especially internationally?

When traveling, official guidance reminds patients to keep the medicine in its original prescription container. It is required that the medicine is kept in its original container, and patients must be aware of the specific storage conditions needed for the prescribed form.


Q: Does LX have any known drug interactions with antacids?

Official information indicates that certain types of antacids, specifically those known as H2 receptor antagonists (like Cimetidine), may potentially delay the absorption of LX. This effect may reduce the peak concentration and potentially lessen the overall effectiveness of the antibiotic.


Q: Can LX cause changes in sleep patterns or vivid dreams?

While the adverse reaction list does not specifically call out vivid dreams, central nervous system effects such as headache, confusion, and nervousness have been reported. These types of effects may indirectly influence a person's sleep patterns.


Q: Are older adults (seniors) more likely to experience certain side effects with LX?

Regulatory documents state that older adults may process drugs more slowly due to age-related changes in kidney function. This can raise the systemic exposure to the drug and potentially raise the risk of side effects; therefore, a lower dose or different dosing schedule may be necessary in some seniors.

How should LX be stored and disposed of?

Official Storage and Disposal Requirements

Cephalexin storage requirements differ based on the form. Capsules and tablets must be stored at controlled room temperature, between 20 C and 25 C (68 F and 77 F), and protected from moisture. The liquid oral suspension, once mixed, requires refrigeration and must not be frozen. The stability of the refrigerated suspension is limited; any unused portion must be discarded after 14 days.

All forms must be kept in a tight container and stored out of the reach of children. Disposal of any unused or expired Cephalexin must align with official local, state, and federal regulations. Recommended disposal methods include using a drug take-back program or following established FDA guidelines for disposal in the household trash, such as mixing the medicine with an unpalatable substance.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of LX found in:

A-Z Index: